Now showing items 1-2 of 2

    • Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. 

      Clarke, PA; Ortiz-Ruiz, M-J; TePoele, R; Adeniji-Popoola, O; Box, G; Court, W; Czasch, S; El Bawab, S; Esdar, C; Ewan, K; Gowan, S; De Haven Brandon, A; Hewitt, P; Hobbs, SM; Kaufmann, W; Mallinger, A; Raynaud, F; Roe, T; Rohdich, F; Schiemann, K; Simon, S; Schneider, R; Valenti, M; Weigt, S; Blagg, J; Blaukat, A; Dale, TC; Eccles, SA; Hecht, S; Urbahns, K; Workman, P; Wienke, D (2016-12-09)
      Mediator-associated kinases CDK8/19 are context-dependent drivers or suppressors of tumorigenesis. Their inhibition is predicted to have pleiotropic effects, but it is unclear whether this will impact on the clinical utility ...
    • Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. 

      Cato, L; Neeb, A; Sharp, A; Buzón, V; Ficarro, SB; Yang, L; Muhle-Goll, C; Kuznik, NC; Riisnaes, R; Nava Rodrigues, D; Armant, O; Gourain, V; Adelmant, G; Ntim, EA; Westerling, T; Dolling, D; Rescigno, P; Figueiredo, I; Fauser, F; Wu, J; Rottenberg, JT; Shatkina, L; Ester, C; Luy, B; Puchta, H; Troppmair, J; Jung, N; Bräse, S; Strähle, U; Marto, JA; Nienhaus, GU; Al-Lazikani, B; Salvatella, X; de Bono, JS; Cato, AC; Brown, M (2017-08-10)
      Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). ...